Sensorion SA (ALSEN.PA)
Paris · EUR · Healthcare · Biotechnology
€8.77 (+1.99%) as of
Key statistics
- Market cap
- 90.40M
- Forward P/E
- -3.92
- EPS (TTM)
- -4.65
- Dividend yield
- 0.00%
- 52-week range
- 5.25 – 40.40
- Beta
- 0.55
- Revenue (TTM)
- 6.16M
- Profit margin
- 0.00%
- Analyst target
- €40.20
- Volume
- 7.40k
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Montpellier, France
- Employees
- 66
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.